Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Interest & Investment Income (2017 - 2025)

Dianthus Therapeutics has reported Interest & Investment Income over the past 8 years, most recently at $1.3 million for Q3 2025.

  • Quarterly results put Interest & Investment Income at $1.3 million for Q3 2025, down 35.98% from a year ago — trailing twelve months through Sep 2025 was $12.8 million (up 40.3% YoY), and the annual figure for FY2024 was $17.4 million, up 264.5%.
  • Interest & Investment Income for Q3 2025 was $1.3 million at Dianthus Therapeutics, up from $406000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for DNTH hit a ceiling of $7.3 million in Q4 2024 and a floor of -$1.7 million in Q4 2022.
  • Median Interest & Investment Income over the past 4 years was $1.2 million (2023), compared with a mean of $1.9 million.
  • Biggest five-year swings in Interest & Investment Income: soared 857.4% in 2024 and later plummeted 90.53% in 2025.
  • Dianthus Therapeutics' Interest & Investment Income stood at -$1.7 million in 2022, then surged by 44.32% to -$960000.0 in 2023, then soared by 857.4% to $7.3 million in 2024, then tumbled by 81.47% to $1.3 million in 2025.
  • The last three reported values for Interest & Investment Income were $1.3 million (Q3 2025), $406000.0 (Q2 2025), and $3.8 million (Q1 2025) per Business Quant data.